Etanercept therapy for psoriasis in a patient with concomitant hepatitis c and liver transplant

Puerto Rico Health Sciences Journal

Volumn 27, Issue 4, 2008, Pages 346-347

  González, José R ^a   Collazo, Michelle H ^b   Torres, Esther A ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b Department of Dermatolology ^*

Author keywords

Etanercept; Hepatitis C; Liver transplant; Psoriasis

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PSORIASIS;

HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 61549089719     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Eng J Med 2003;349: 2014-2022.
2. Mease PJ. Current treatment of psoriatic arthritis. Rheum Dis Clin North Am 2003;29:495-511.
3. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-486.
4. Quartier P, Taupin P, Bourdeau F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-1101.
5. David JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylotis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236.
6. Drewe E, Huggings ML, Morgan AG, et al. Treatment of renal amyloidosis with etanercept in tumor necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004;43:1405-1408.
7. Sá́nchez Carazo JL, Mahiques Santos L, Oliver Martínez V. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006;29: 675-685.
8. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial al etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British J Dermatol 2005;152:1304-1312.
9. Peterson JR, Wener MH, Hsu FC. Safety of TNF-α antagonists in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis 2002;61:38-40.
10. Z ein NN, Etanercept Study Group. A phase II randomized, double blind, placebo controlled study of tumor necrosis factor antagonist (etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naïve patient with chronic hepatitis C. 52nd Annual Meeting of the American Association for the Study of Liver Diseases 2002, 101808(abstr.).